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Transgenic overexpression of prothymosin a induces develop-
ment of polycystic kidney disease.
Background. Polycystic kidney disease (PKD) is a genetic dis-
order characterized by development of renal cysts and progres-
sive renal dysfunction. Renal tissues from both PKD patients
and rodent models of PKD show elevated c-myc expression.
Prothymosin a (ProT) is positively regulated by c-myc through
binding to the E box of its promoter. Through creating trans-
genic mice and clinical studies, we sought to investigate whether
ProT overexpression contributes to PKD development.
Methods. ProT heterozygous and homozygous transgenic
mice were generated and characterized. Morphologic, histo-
logic, immunohistochemical, and biochemical analyses of the
transgenic mice were performed.
Results. Two transgenic lines that represented integration at
two different loci of the chromosomes were generated. ProT
overexpression in the kidneys of homozygous transgenic mice
induced a PKD phenotype, which included polycystic kidneys,
elevated blood urea nitrogen (BUN), and lethality at about 10
days of age. Similar overexpression pattern of ProT was noted
in cystic kidneys of the transgenic mice as well as in human
autosomal-recessive PKD (ARPKD) and autosomal-dominant
PKD (ADPKD) kidneys. ProT protein levels in the kidneys
and urine as well as renal mRNA level of epithelial growth
factor receptor (EGFR) of homozygous ProT transgenic mice
were significantly higher than heterozygous or nontransgenic
littermates. Furthermore, the heterozygous transgenic mice at
17 months of age also developed mild cystic kidneys.
Conclusion. Transgenic mice overexpressing ProT represent
a novel model for PKD and may provide insights into PKD de-
velopment. ProT, like c-myc and EGFR, may contribute to the
development of renal cysts and may be a potential noninvasive
diagnostic molecule of PKD.
Polycystic kidney disease (PKD), which is potentially
fatal, is one of the most common genetic disorders. The
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massive enlargement of the kidneys due to the build-up
of fluid-filled cysts eventually leads to functional failure
in a high proportion of cases. Autosomal-recessive PKD
(ARPKD) and autosomal-dominant PKD (ADPKD) are
the two major inheritable forms of PKD in humans [1].
ARPKD is a rare defect, and infants born with ARPKD
die from renal failure shortly after birth. In ADPKD, cyst
formation also occurs during development; however, the
disease is usually only detected in the third decade of
life. By late middle age, patients with ADPKD may also
suffer from renal failure. The neoplastic nature of renal
cysts has been recognized for several years [2]. A num-
ber of animal models for ADPKD and ARPKD, includ-
ing DBA-2J-cpk/cpk, C57BL/6J-cpk/cpk, CD-1cpk/cpk,
BALB/c-bpk/bpk, and BALB/c-cpk/cpk mice, as well
as Han:SPRD cy/+ rats, have been established [3–8].
Among many genes examined, elevated c-myc expres-
sion was observed in all forms of PKD in humans and
animal models [8–13].
Prothymosin a (ProT), which was first isolated from rat
thymus [14, 15], is a highly acidic protein with widespread
tissue distribution. As ProT was thought to be the puta-
tive precursor of thymosin a1, earlier studies have fo-
cused on its immunomodulatory effect, especially on T
cells [16]. However, accumulating evidence indicates that
ProT is an essential protein related to cell proliferation
[17–19]. Our previous study also showed that overexpres-
sion of ProT accelerates cell proliferation by shortening
the duration of the G1 phase of the cell cycle [20]. ProT
may exert diverse biologic functions through its interac-
tion with histone H1 protein to affect chromatin remod-
eling [21, 22], and with procaspase 9 to affect cell death
[23]. In addition, ProT gene is one of the target genes of
myc that is encoded by the proto-oncogene c-myc [24].
Myc directly regulates the expression of ProT gene by
binding to the E box of its promoter [25, 26]. Although
many biologic functions of ProT have been revealed by
these studies, the physiologic roles of ProT in vivo remain
largely unclear.
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Table 1. Primer pairs used for polymerase chain reaction (PCR) or reverse transcription (RT)-PCR
Specificity Nucleotide sequence (5′ to 3′) Location Fragment (bp)
ProT RAP-fa (TGAGCGAGCCGGAGCCAA) b-actin promoter 857
ProT-rb1 (GTAGTTTTGGAGGGGTGGTGGAGAG) ProT gene
ProT MCS-f (TCTAGAGGATCCCCGGGCGAGCTC) Multiple cloning site in pJ6-ProT 875
minigene construct
ProT-r2 (ACGCTCTGAAGGCTGGTTTGGTC) ProT gene
c-Myc c-Myc-f (AGCCCTATTTCATCTGCGACGAG) c-myc gene 1100
c-Myc-r (GGATGTAGGCGGTGGCTTTTTTG) c-myc gene
EGF EGF-f (CTCGCCTTCCTGCTGGTGTTTTT) EGF gene 640
EGF-r (ACCCAGAAGAGCCGTTTGTCCAG) EGF gene
EGFR EGFR-f (AGTTTTCTTTGGCGGTCGTTGGC) EGFR gene 730
EGFR-r (TGGAAGAAACTGGAAGGTGAGAGGG) EGFR gene
18S rRNA 18S rRNA-f (TATGGTTCCTTTGGTCGCTCG) 18S rRNA gene 415
18S rRNA-r (ATTTTTCGTCACTACCTCCCCG) 18S rRNA gene
Abbreviations are: ProT, prothymosin a, EGF, epithelial growth factor; EGFR, epithelial growth factor receptor.
aDenotes forward primer; bDenotes reverse primer.
c-myc regulates the expression of ProT gene [25–27]
and elevated c-myc expression is observed in all forms
of PKD in humans and animal models [8–13]. There-
fore, we speculated that overexpression of the ProT gene
may contribute to the development of PKD. In this study,
we describe the generation of transgenic mice with ProT
overexpression driven by the b-actin promoter. The ho-
mozygous transgenic mice reproducibly developed mor-
phologic and functional alterations characteristic of PKD,
and died 10 days after birth. The relevance of this model
to the human disease is further supported by ProT over-
expression noted in both human ARPKD and ADPKD
kidneys. Our results suggest that ProT overexpression
may play a role in the development of PKD. ProT trans-
genic mice represent a novel model for PKD and may
provide insights into potential pathogenetic mechanisms
resulting in PKD.
METHODS
Construction and identification of transgenic mice with
overexpression of a ProT minigene
The ProT minigene construct (Fig. 1A) used to gen-
erate transgenic mice was pJ6-ProT, which contained
a complete 1.2 kb murine ProT cDNA together with
the rat b-actin promoter and SV40 polyadenylation tail
[20]. The ubiquitous b-actin promoter has been reported
to direct widespread gene expression in transgenic mice
[28, 29]. The minigene, which was excised from pJ6-
ProT by PvuII and ScaI digestions, was microinjected
into the pronucleus of FVB zygotes, and the injected eggs
were transferred into the oviduct of pseudopregnant re-
cipients. Genomic DNA of founder mice was extracted
from tail biopsies and the integration of the transgenic
ProT minigene was detected by polymerase chain reac-
tion (PCR) using RAP-f and ProT-r1 primers (Table 1).
The PCR reaction was performed at an annealing tem-
perature of 60◦C for 35 cycles. Analysis for the presence
of the transgene was performed by dot blot analysis of ge-
nomic DNA using 32P-labeled murine ProT cDNA as the
hybridization probe. The copy number of the transgene
was determined by comparing the intensity resulting from
0.5 lg, 1 lg, and 2.5 lg genomic DNA among wild-type,
nontransgenic, and transgenic founders, respectively, on
dot blot analysis by densitometry. All animal experiments
were performed following the guidelines approved by the
Laboratory Animal Care and Use Committee of the Na-
tional Cheng Kung University Medical College.
Quantification of transgene expression by reverse
transcription (RT)-PCR
Total RNA from a variety of mouse tissues was iso-
lated with RNeasy Mini Kit (Qiagen, Hilden, Germany).
To avoid genomic DNA contamination, RNA was treated
with DNase I for 15 minutes, and reverse transcribed at
47◦C using oligo-dT (0.5 lg/lL) and reverse transcrip-
tase in a total volume of 20 lL. The RT reaction product
(3 lL) was mixed with 10 × reaction buffer (5 lL) con-
taining 5 mmol/L deoxynucleoside triphosphate (dNTP)
mix, Taq DNA polymerase, and 3 lmol/L of each oligonu-
cleotide primer. The primer pairs used for amplification
of ProT, c-myc, epithelial growth factor (EGF), EGF re-
ceptor (EGFR), and 18S rRNA mRNA serving as the
internal control for RT-PCR are shown in Table 1. All
amplified products were confirmed by DNA sequencing.
RT-PCR products were quantified by densitometric scan-
ning of the electrophoresis bands and related to the band
intensity of the 18S rRNA gene.
Flow cytometry
Staining of cell surface antigens was performed by
incubating splenocytes or thymocytes of ProT heterozy-
gous (7 weeks old), homozygous (10 days old) transgenic,
or age-matched wild-type mice for 60 minutes at 4◦C in
the presence of NaN3, with fluorochrome-conjugated
rat antimouse monoclonal antibodies, including
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145-2C11 (anti-CD3e)-phycoerythrin-Cy5 (Pharmingen,
San Diego, CA, USA), GK1.5 (anti-CD4)-R-phyco-
erythrin (Pharmingen), and 53–6.7(anti-CD8)-
fluorescein isothiocyanate (FITC) (Pharmingen).
The percentage of cell subpopulation was determined
using a FACSCalibur flow cytometer (Becton Dickinson,
San Jose, CA, USA) and CellQuest software (Becton
Dickinson). At least 10,000 gated events were acquired
per antibody analyzed.
Quantification of ProT protein by enzyme-linked im-
munosorbent assay (ELISA)
Lysate was prepared from homogenization of whole
kidney in 300 lL radioimmunoprecipitation assay
(RIPA) buffer [1% Nonidet P-40, 0.5% deoxycholic acid,
and 0.2% sodium dodecyl sulfate (SDS) in phosphate-
buffered saline (PBS)] with complete protease inhibitor
cocktail (Roche, Penzberg, Germany). The insoluble
fraction was removed by centrifugation at 12,000 rpm for
15 minutes. The protein content of each kidney lysate was
measured using a BCA Protein Assay Kit (Pierce, Rock-
ford, IL, USA). Urine samples were collected from mice
for ProT measurements after depriving them of liquid for
12 hours.
We have previously generated mouse monoclonal and
rabbit polyclonal antibodies against recombinant human
ProT produced in Escherichia coli. They were employed
in an antibody-sandwich ELISA for determining renal
and urinary ProT contents in mice [20]. In brief, 96-well-
microtiter plates (MaxiSorp, Nunc, Roskilde, Denmark)
were coated with rabbit anti-ProT polyclonal antibody
(2 lg/mL in 0.2 mol/L carbonate-bicarbonate buffer, pH
9.6) at 37◦C for 5 hours and blocked with 1% bovine
serum albumin (BSA) diluent/blocking solution (KPL,
Gaithersburg, MD, USA) at 37◦C for 2 hours. After re-
moval of the blocking agent, mouse urine (15 lL) diluted
1:2 in 1% BSA was added in duplicate and plates were
incubated overnight at 4◦C. After washings with PBS-
T [0.05% (vol/vol) Tween-20 in PBS], anti-ProT mono-
clonal antibody (ascites, 5 lg/mL, 100 lL) was added at
37◦C for 2 hours. After washings with PBS-T, horseradish
peroxidase–conjugated goat anti-mouse IgG + IgM anti-
body (KPL) was added and the plates were incubated at
37◦C for 2 hours. The plates were washed and 3, 3′, 5, 5′-
tetramethyl benzidine was added. After a further incuba-
tion at room temperature for 40 minutes, the reaction was
stopped by adding 2 mol/L H2SO4 and the absorbance at
450 nm was measured by an ELISA reader. Twofold dilu-
tions of recombinant human ProT protein ranging from
0.001 to 0.01 lg/mL were used as the standard in the assay.
Histologic, immunohistochemical, and biochemical anal-
yses of kidneys
Mice were sacrificed via cervical dislocation, and per-
fusion was performed with calcium- and magnesium-free
PBS. Kidneys were removed and fixed in 10% forma-
lin at 4◦C overnight. The tissues were dehydrated and
embedded in paraffin, and sectioned at 5 lm for im-
munostaining or hematoxylin-eosin staining. Segment-
specific localization of renal cysts was assessed im-
munohistologically using biotinylated Dolichos biflorus
agglutinin (1:500) (Vector Laboratories, Burlingame, CA,
USA) specific to collecting tubule [30], rabbit antibody
against human Tamm-Horsfall protein (1:500) (Biomed-
ical Technologies, Stoughton, MA, USA), a marker for
distal tubule [31], and rabbit antibody against human
lysozyme (1:300) (Dako, Glostrup, Denmark), a marker
for proximal tubule [32]. Three human kidney speci-
mens from PKD cases obtained from the Department
of Pathology, National Cheng Kung University Hospital
were immunohistochemically investigated for the pres-
ence of ProT protein. Case 1 had ADPKD with chronic
renal failure due to severe tubulointerstitial nephritis,
while cases 2 and 3 had ARPKD. Case 2 at 30 weeks
of gestational age was diagnosed premature ARPKD
with mega-kidney and terminated due to polycystic kid-
ney. Case 3 at 31 weeks of gestational age was diag-
nosed prenatal ARPKD with mild congenital hepatic fi-
brosis. To detect ProT expression, kidney sections from
ProT transgenic mice and from clinical specimens were
blocked with an avidin/biotin blocking kit (Vector Labo-
ratories) after deparaffinization and rehydration, and in-
cubated overnight at 4◦C with rabbit anti-ProT antibody
(1:100) (Calbiochem, San Diego, CA, USA). Immunos-
taining was performed using a commercial streptavidin-
biotin alkaline phosphatase complex Dako LSAB 2 Kit
(Dako) according to the manufacturer’s instructions, us-
ing aminoethyl carbazole (AEC) staining and hema-
toxylin counterstaining. Masson trichrome stain was used
to determine the extent of interstitial fibrosis in the kid-
ney and liver. Serum samples were collected for determi-
nation of blood urea nitrogen (BUN) by a colorimetric
assay kit (Ecoline 25) (Merck, Darmstadt, Germany).
Statistics
Data are expressed as mean ± SD. Statistical analy-
sis was conducted by using the two-tailed Student t test.
Statistical significance was defined as P < 0.05.
RESULTS
Generation and identification of transgenic mice overex-
pressing ProT
To generate ProT transgenic mice, microinjection of
the linearlized ProT minigene (Fig. 1A) into the pronuclei
of fertilized FVB embryos was performed using standard
techniques. Genomic DNA from tail biopsies was iso-
lated and examined for the presence of ProT transgene
by PCR using RAP-f and ProT-r1 primers, which were
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Fig. 1. Generation and characterization of prothymosin a (ProT) transgenic founder lines. (A) Schematic diagram of the ProT transgene construct
used to create transgenic mice. A transgene construct consisting of the rat b-actin promoter, full-length mouse ProT cDNA, and the SV40 large
T antigen polyadenylation signal sequence was generated. Restriction sites for excision of the construct from the cloning vector (PvuII/ScaI), for
generation of radiolabeled probe (EcoRI), and for digestion of genomic DNA for Southern blot analysis (PvuII) are indicated. Locations of primers
for amplifying 857 bp (RAP-f and ProT-r1) and 875 bp (MCS-f and ProT-r2) products in polymerase chain reaction (PCR) and reverse transcription
(RT)-PCR analyses are shown, respectively. (B) PCR screening of the transgene using tail DNA. The presence of an 857 bp PCR product indicates
the ProT transgenic founder. Lane C1 represents the mixture of linear transgene and genomic DNA from normal mice, which served as a positive
control. Lane C2 represents genomic DNA from normal mice, which served as a negative control. Numbers 1 to 12 represent 12 different offspring.
(C) Localization of the transgene (T) in two identified founders was determined by Southern blot analysis. Different PvuII restriction patterns were
observed in T9 and T12 compared with wild-type (W) and nontransgenic (NT) mice. (D) The copy number of transgene integrated into the genome
of T9 and T12 founder lines ranged between three and five copies per haploid genome, as determined by densitometric comparison on DNA dot
blot analysis. b-actin served as an internal control.
designed to exclude amplification of endogenous ProT
gene. The expected 857 bp PCR product should be de-
tected in the F0 offspring. Occasionally, embryonic lethal-
ity was encountered. Among 12 offspring examined,
two male founders (T9 and T12) that revealed positive
genomic integration of the transgene were established
(Fig. 1B). The authenticity of the PCR product was fur-
ther confirmed with DNA sequencing (data not shown).
Localization of the minigene in T9 and T12 founders
was determined by Southern blot analysis. As shown in
Figure 1C, different restriction patterns between T9 and
T12 were noticed, suggesting that these two founders
were independent lines and ProT transgene was local-
ized at different loci. The copy number of transgene in-
tegrated into the genome of these mice ranged between
three and five copies per haploid genome, as determined
by densitometric comparison on DNA dot blot analysis
(Fig. 1D). Transgenic founder mice were used to estab-
lish transgenic mouse lineages. Unless otherwise noted,
the fifth (F5) and sixth (F6) generation mice at 10 weeks
of age were used throughout the experiments.
Analysis of ProT gene expression in transgenic mice
To determine whether ProT minigene was expressed in
transgenic mice, we analyzed ProT mRNA expressions in
the spleen, thymus, lung, liver, and kidney from the off-
spring of both founder lines by semiquantitative RT-PCR
using MCF-f and ProT-r2 primers (Fig. 1A). Expression
of ProT transgene was detected in all the tissues examined
from T12 transgenic offspring, but not in nontransgenic
littermates (Fig. 2A). Similar results were also obtained
from T9 transgenic offspring (data not shown). However,
no obvious phenotypical alterations were observed in
these founder lines and their offspring which were born
from the founder mating with wild-type animals. They
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Fig. 2. Transgene expression in prothymosin
a (ProT) transgenic mice. (A) ProT transgenic
RNA expression was detected in various or-
gans in T12 transgenic (T) offspring, but not in
nontransgenic (N) littermates by semiquanti-
tative reverse transcription-polymerase chain
reaction (RT-PCR) using primers specific for
the mouse ProT transgene. Similar results
were also obtained from T9 transgenic off-
spring (data not shown). 18S rRNA expres-
sion served as the quantitative control. M is
100 bp DNA ladder as molecular size stan-
dard. (B) Southern blot of EcoRI-digested
genomic DNA from homozygous (lane 7),
heterozygous (lanes 1 to 4 and 6), and non-
transgenic (lane 5) mice hybridized with a
ProT probe. The 1.2 kb and 3.7 kb bands cor-
respond to transgenic and endogenous ProT,
respectively. (C) ProT transgenic RNA ex-
pression was detected in various organs in
homozygous (HZ) and heterozygous (HET)
ProT mice, but not in nontransgenic (NT) lit-
termates by RT-PCR using primers specific for
the mouse ProT transgene. 18S rRNA expres-
sion served as the quantitative control. M is
100 bp DNA ladder as molecular size stan-
dard.
were then bred to homozygous state to double the level
of transgene expression. Homozygous transgenic mice
were generated from heterozygous breeding pairs and
the genotype was determined by Southern blot analysis.
As shown in Figure 2B, the copy number of transgene
in homozygous transgenic mice was doubled compared
with that for heterozygous transgenic mice. Expression
of the ProT transgene was observed in all the organs ex-
amined, including spleen, thymus, lung, liver, and kidney.
As expected, the level of ProT transgenic mRNA expres-
sion in the homozygous mice was higher than that in their
heterozygous littermates (Fig. 2C). Among these organs,
higher expression of ProT transgene was detected in the
kidney and lung compared with the liver, spleen, and
thymus.
Morphologic and immunologic analyses of ProT trans-
genic mice
As shown in Figure 3A, birth weight of homozygous
ProT mice was reduced to approximately 70% of the
weight of their heterozygous or nontransgenic litter-
mates. The homozygous mice were fed very poorly during
the first few hours of life. Furthermore, they gained less
weight and were approximately half the size of their het-
erozygous or nontransgenic littermates at 10 days of age.
Whereas all the homozygous mice inevitably succumbed
to death approximately 10 days after birth, the heterozy-
gous mice appeared normal and survived their normal
life span. Figure 3B shows that the homozygous mouse
was smaller and retarded in growth rate compared with
heterozygous or nontransgenic littermates at 10 days of
age. Morphologic examinations revealed that the thymus,
lung, liver, and spleen of the homozygous mice were all
smaller than the corresponding organs of age-matched
heterozygous or nontransgenic littermates. However, on
a percentage of body weight basis, the relative weight
was significantly increased in the kidney and liver, but
remained constant in the lung, spleen, and thymus of ho-
mozygous ProT mice (Fig. 3C). The following values were
found for the ratio of kidney weight to body weight: ho-
mozygous ProT mice, 0.058 ± 0.014 g (2.350 ± 0.290%)
of 2.35 ± 0.32 g; heterozygous ProT mice, 0.060 ± 0.004
g (1.160 ± 0.068%) of 5.20 ± 0.21 g; and nontransgenic
mice, 0.060 ± 0.004 g (1.136 ± 0.071%) of 5.26 ± 0.22
g. Therefore, the homozygous mice had similar kidney
size but increased ratio of kidney weight to body weight,
displaying renal enlargement with smooth surfaces
(Fig. 3D). The 10-day-old homozygous ProT mice had
no obvious abnormalities in the spleen and thymus, nor
did their splenic CD4+ and CD8+ T cells change in rel-
ative percentage (data not shown). Analysis on thymus
and spleen cells of 7-week-old heterozygous ProT mice
did not reveal any major differences in populations of
CD4+ and CD8+ T cells in either cell numbers or rela-
tive percentage (data not shown). However, it remains
to be determined whether T-cell functions are affected in
ProT transgenic mice. Notably, although the morphology
of lungs from newborn homozygous ProT mice appeared
normal, emphysematous changes and slight fibrosis of the
lung were observed when they were 10 days of age [Li KJ,
Shiau AL, and Wu CL, manuscript in preparation]. How-
ever, little apparent change in the gross morphology of
the lung was found in heterozygous ProT mice.
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Fig. 3. Gross phenotypes of prothymosin
a(ProT) transgenic mice. (A) Growth curves
for body weight and (B) photographs of ho-
mozygous (HZ), heterozygous (HET), and
nontransgenic (NT) littermates. (C) Ratios
of organ weight to body weight for the
spleen, thymus, lung, liver, and kidney in ho-
mozygous, heterozygous, and nontransgenic
mice. (D) Photographs showing the kidneys
of homozygous (0.0286 g) and nontransgenic
(0.0298 g) littermates at 10 days of age.
Histologic analysis of ProT transgenic mice
Abnormalities in both kidney and lung were noticed in
the homozygous mice upon histological analysis. A total
of 16 kidneys from 16 homozygous mice, 12 at 10 days of
age, and 4 at 1 day of age, as well as equivalent samples
from heterozygous mice and their nontransgenic litter-
mates underwent histologic analysis. Independent of age,
all kidney specimens from homozygous ProT mice dis-
played a polycystic phenotype (Fig. 4A to D) in contrast
to the normal appearing kidneys from heterozygous (data
not shown) and nontransgenic littermates (Fig. 4E to H).
Bilateral diffusely distributed renal cysts and hyperpla-
sia of renal epithelium were observed in the homozygous
mice. The cysts of newborn mice exclusively occurred in
the inner cortex and medulla (Fig. 4A and B), and then
predominantly developed in medulla generally at 10 days
of age (Fig. 4C and D). Furthermore, the cysts were larger
in the homozygous mice at 10 days of age (Fig. 4C and D)
compared with those in the newborn mice (Fig. 4A and
B). At birth, cysts were localized throughout collecting
(Fig. 5A), distal (Fig. 5C), and proximal (Fig. 5E) tubu-
lar segments, whereas at 10 days in the terminal stages
of the disease, cysts presented prominently in collecting
(Fig. 5B) and distal (Fig. 5D) tubules, but not in proxi-
mal tubules (Fig. 5F). In addition, slight renal fibrosis of
homozygous ProT mice was detected as assessed by Mas-
son trichrome staining (data not shown). However, liver
fibrosis, a feature associated with some human forms of
PKD, was not noted in these mice (data not shown).
We also examined four 17-month-old heterozygous
ProT transgenic mice in each independent line. Morpho-
logic examination revealed that their lungs, livers, and
spleens were not different from those of nontransgenic
littermates, whereas all of their kidneys displayed a small
degree of phenotypic alterations. Visible cysts, albeit to a
lesser extent compared to young homozygous mice, were
observed in their kidneys (Fig. 6A), which were confirmed
by histologic analysis (Fig. 6B). As detailed examinations
of the lung in the aged heterozygous mice have not yet
been carried out, histologic changes in the lungs cannot
be ruled out and need to be investigated further.
Increased levels of ProT production in the kidney and
urine of homozygous ProT transgenic mice
To determine whether PKD found in ProT transgenic
mice was associated with an increase of ProT, we deter-
mined the ProT levels in the kidneys of ProT transgenic
mice. As shown in Figure 7A, the ProT level, corrected for
protein content, in the kidneys of homozygous ProT mice
was more than two times higher than that of heterozygous
or nontransgenic littermates (Fig. 7A). Furthermore, the
concentration of ProT in urine (52.29 ± 2.8 pg/lL) was
approximately tenfold higher in the homozygous mice
than that of heterozygous or nontransgenic littermates
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Fig. 4. Formation of renal cysts in homozy-
gous prothymosin a (ProT) transgenic mice.
Hematoxylin-eosin stains on kidney sections
from newborn and 10-day-old homozygous
and nontransgenic littermates. Cysts pre-
sented in the kidneys of homozygous ProT
mice at newborn (A and B) and at 10 days
of age (C and D), whereas the kidneys of
nontransgenic littermates, either at newborn
(E and F) or at 10 days of age (G and H),
appeared normal [original magnification ×10
(A, C, E, and G) and ×200 (B, D, F, and H)].
C is cortex; M is medulla.
(Fig. 7B). These results indicate that polycystic kidney
found in ProT transgenic mice was associated with in-
creased expression of ProT.
Correlation between the murine PKD model induced by
ProT overexpression and human PKD
To understand the pattern of ProT overexpression in
cystic kidneys of homozygous and aged heterozygous
ProT mice, ProT expression in renal tissue was examined
by immunohistochemistry. ProT expression was localized
abundantly in the cystic epithelium of homozygous ProT
mice (Fig. 8A), in contrast to low expression in renal tubu-
lar epithelium of nontransgenic littermates (Fig. 8C). To
further explore whether PKD induced by ProT overex-
pression in transgenic mice resembled human PKD, renal
specimens of three PKD cases were examined for ProT
expression. Interestingly, the expression patterns of ProT
in the clinical specimens (Fig. 8I) were similar to those
of ProT homozygous (Fig. 8A) and aged heterozygous
transgenic mice (Fig. 8E), whereas ProT was hardly de-
tectable in the kidney of normal individuals (Fig. 8K).
The tissue sections shown in Figure 8I and J were from
case 2 (ARPKD). Similar expression patterns and levels
of ProT were also noted in cases 1 and 3 suffering from
ADPKD and ARPKD, respectively (data not shown).
These clinical findings suggest that increased expression
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Fig. 5. Location of renal cysts in homozy-
gous prothymosin a (ProT) transgenic mice.
Segment-specific localization of cysts from the
kidneys of the newborn (A, C, and E) and
10-day-old (B, D, and F) homozygous ProT
mice was assessed immunohistologically using
Dolichos biflorus agglutinin specific to collect-
ing tubule (A and B), antibody that recognizes
Tamm-Horsfall protein, a marker for distal
tubule (C and D), and antibody that recog-
nizes lysozyme, a marker for proximal tubule
(E and F) (original magnification ×200).
of ProT may be a common feature of different forms of
PKD. Collectively, ProT was present abundantly in the cy-
toplasm of cystic epithelium in both animal models and
clinical specimens of PKD, but scarcely in renal tubule
epithelium from nontransgenic mice and normal individ-
uals. These results suggest that overexpression of ProT
may lead to the development of PKD.
To evaluate whether the lethality in the homozygous
mice was due to the deterioration of renal function, serum
levels of BUN, another major characteristic of PKD in hu-
mans and in congenital mouse models, were measured.
As shown in Figure 9, the levels of BUN in heterozy-
gous ProT mice (24.79 ± 1.25 mg/dL) and nontransgenic
mice (23.93 ± 1.01 mg/dL) were similar. In contrast, BUN
values of the homozygous mice were nearly three times
higher than those of heterozygous or nontransgenic litter-
mates. Notably, the BUN levels in the homozygous mice
killed in a moribund state were approximately five times
higher than those of heterozygous or nontransgenic lit-
termates, reaching a value of 120 mg/dL. These results
suggest that renal failure, at least in part, might be a pos-
sible cause of death in homozygous ProT transgenic mice.
Up-regulation of EGFR expression in homozygous ProT
transgenic mice
To further investigate how ProT overexpression in-
duced PKD, expressions of several genes thought to be
associated with PKD, namely c-myc, EGFR, and EGF,
were examined by RT-PCR in the kidneys of ProT trans-
genic mice obtained from both T9 and T12 lines. The
results shown are representative of four independent ex-
periments (Fig. 10). As expected, the expression level
of ProT transgenic RNA in the homozygous mice was
higher than that in the heterozygous mice. The expres-
sion levels of c-myc and EGF in homozygous ProT
mice remained unchanged compared with those in het-
erozygous or nontransgenic littermates. However, in ac-
cordance with PKD in humans [33] and in congenital
mouse models of PKD [34, 35], significant up-regulation
of EGFR mRNA expression was detected in homozy-
gous ProT transgenic mice. Comparative densitomet-
ric analysis of various RT-PCR products relative to 18S
rRNA product revealed significant augmentation of renal
mRNA expression of EGFR in homozygous ProT mice
(Fig. 10B).
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Fig. 6. Gross appearance of the kidneys from aged heterozygous pro-
thymosin a (ProT) transgenic and nontransgenic mice. (A) Photographs
showing the difference of the kidneys between heterozygous (HET) and
nontransgenic (NT) mice at 17 months of age. Cysts were consistently
observed in the kidneys of aged heterozygous but not in age-matched
nontransgenic mice. The arrows indicate the location of cysts. (B) A few
cysts of various sizes were always seen in the hematoxylin-eosin–stained
kidney section from aged ProT transgenic mice, but not in nontransgenic
mice (original magnification ×10). The insets represent the magnified
area (original magnification ×100).
DISCUSSION
In this study, we describe the generation and charac-
terization of a novel animal model for PKD by transgenic
overexpression of ProT. Similar to other congenital PKD
mice [3], homozygous ProT transgenic mice were fed very
poorly during the first few hours of life, and their body
sizes were smaller than heterozygous or nontransgenic
littermates. The homozygous ProT mice also revealed
growth retardation with age, and finally died about 10
days after birth, while congenital PKD mice die at the
age of 3 to 4 weeks [3–7]. Based on histological analy-
sis, bilateral diffusely distributed renal cysts and hyper-
plasia of renal epithelium were observed in homozygous
ProT transgenic mice. Particularly, cyst development in
the ProT transgenic mice is very similar to other con-
genital PKD mouse models, in which renal cyst forma-
tion occurs in the proximal tubules and collecting ducts
at birth and predominantly in collecting ducts at the age
of 10 days [3–7]. Of note, renal cysts also presented in the
distal tubules of homozygous ProT mice. Furthermore, al-
though the kidney size remained largely unchanged, the
kidney weight/body weight ratio of homozygous ProT
mice was greater compared with that of heterozygous
or nontransgenic littermates, suggesting that overexpres-
sion of ProT resulted in progressive kidney enlargement
of postnatal mice and increased fatality in infants. The
moribund homozygous ProT mice had fivefold higher
BUN levels than did age-matched heterozygous or non-
transgenic littermates. In some congenital PKD mouse
models [3, 5–7], in addition to renal pathology, hepatic
cysts and bile duct cysts are the most common extrarenal
pathology. However, these pathological changes were not
noted in homozygous ProT transgenic mice. Although the
homozygous mice presented high levels of BUN, they dis-
played only a small degree of renal fibrosis. Notably, large
emphysematous air spaces were observed in the lungs,
which may have reduced air exchange efficiency in alve-
olar duct, leading to respiratory failure. Therefore, in ad-
dition to impaired renal function, pulmonary emphysema
may have contributed to the early death of homozygous
ProT mice. It is of interest to note that higher levels of
ProT mRNA were expressed in the kidney and lung than
in the liver, spleen, and thymus in homozygous ProT mice,
which correlated with phenotypic alterations found in the
kidney and lung. The ProT transgene was driven by the
ubiquitous b-actin promoter to give widespread expres-
sion in transgenic mice. However, it has been shown that
b-actin gene may not be constitutively expressed under
some circumstances. In the folic acid–induced regenera-
tive hyperplasia model in rabbits, kidney epithelial cells
revealed rapid, transient increases in b-actin mRNA [36].
This suggests that higher expression of transgenic ProT
driven by the b-actin promoter may have occurred in
proliferating cells, such as cystic epithelial cells, of ProT
transgenic mice. ProT expression may further promote
cell proliferation, resulting in a positive feedback regula-
tion on ProT expression. Furthermore, in mouse tissues,
lung and kidney are the two nonlymphoid tissues to ex-
press the highest level of endogenous ProT [37], which
accords with the highest expression of ProT mRNA in
ProT transgenic mice. Our results demonstrate that renal
and pulmonary functions of homozygous ProT transgenic
mice deteriorated rapidly after birth and all the mice in-
evitably died approximately 10 days after birth.
In the present study, similar PKD phenotypes were
consistently observed in two independent transgenic
lines, suggesting that the phenotype of homozygous ProT
transgenic mice was attributable to ProT overexpres-
sion, rather than inactivation of genes associated with
transgene integration. The two founder lines that we
established contained three to five copies of the ProT
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Fig. 7. Increased expression of renal and uri-
nary prothymosin a (ProT) protein in ho-
mozygous ProT transgenic mice. ProT pro-
tein level was analyzed by enzyme-linked im-
munosorbent assay (ELISA) in renal extrac-
tion (A) and urine (B) from homozygous
(HZ), heterozygous (HET), and nontrans-
genic (NT) mice. ∗P < 0.05 for homozygous
vs. nontransgenic; ∗∗∗P < 0.001 for homozy-
gous vs. nontransgenic or heterozygous.
Fig. 8. Immunohistochemical examination of prothymosin a (ProT) in the kidneys of homozygous ProT transgenic mice and human polycystic
kidney disease (PKD). ProT expressions in representative tissue sections (original magnification ×400) of the kidneys from 10-day-old homozygous
ProT (A and B) and nontransgenic mice (C and D), from 17-month-old heterozygous ProT (E and F) and nontransgenic mice (G and H), and
from human autosomal-recessive PKD (ARPKD) case (I and J) and normal individuals (K and L) were determined by immunostain with rabbit
antibody against ProT (A, C, E, G, I, and K) or with control rabbit serum (B, D, F, H, J, and L). The arrowhead indicates dark staining for ProT
in cystic epithelial cells from ProT transgenic mice and from human ARPKD case, while the arrow indicates pale staining for endogenous ProT in
renal tubule cells from nontransgenic mice and from normal individuals.
transgene. However, we were unable to obtain transgenic
lines containing higher copy numbers of the transgene. It
is conceivable that very high levels of ProT expression
may have been detrimental to mice, resulting in embry-
onic lethal phenotype or early mortality. As a result, het-
erozygous mice overexpressing ProT but not to a level
high enough to cause phenotypic alterations would grow
normally and were expected to be selected as founders
in our initial screening of heterozygous transgenic mice.
They were then bred to homozygous state to double the
level of transgene expression. All of the homozygous
ProT mice developed PKD and died around 10 days
after birth. Interestingly, although young heterozygous
ProT mice appeared normal and had no obvious pheno-
typical alterations, 17-month-old heterozygous mice did
develop mild PKD with ProT expression detectable in
their cystic epithelium. This result suggests that intracel-
lular accumulation of ProT increased as ProT transgenic
mice grew older, which might lead to PKD. The same
ProT expression pattern was detected in the kidneys of
ProT transgenic mice that displayed slight renal fibrosis,
as well as in those of human ARPKD and ADPKD. Taken
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Fig. 9. Increase of blood urea nitrogen (BUN) in homozygous prothy-
mosin a (ProT) transgenic mice. The levels of BUN in 10-day old ho-
mozygous (HZ), moribund homozygous (HZ-M), heterozygous (HET),
and nontransgenic (NT) mice as determined by a colorimetric assay.
∗∗∗P < 0.001 for homozygous vs. nontransgenic or heterozygous, and
moribund homozygous vs. nontransgenic or heterozygous.
together, these results suggest that ProT overexpression
appeared to be associated with PKD rather than with ure-
mia/azotemia. However, as end-stage kidneys from other
forms of chronic kidney disease were not examined in
this study, whether ProT overexpression is also related
to uremia/azotemia is unclear, which warrants further in-
vestigation.
The proto-oncogene c-myc encodes a transcription fac-
tor that plays a pivotal role in cell proliferation, differen-
tiation, and apoptosis. Overexpression of c-myc induces
PKD in transgenic mice [11, 12]. In human ADPKD, renal
c-myc expression is elevated up to 15-fold, which corre-
lates with increases of both proliferation and apoptosis
in cystic epithelium [13]. Increasing evidence supports
an important role for EGF/transforming growth factor-
a (TGF-a)/EGFR axis in promoting tubular epithelial
cell proliferation and cyst formation in PKD. EGFR and
Erb-B2 (an EGFR-related tyrosine kinase receptor) are
overexpressed and mislocalized to the apical membrane
of the cystic epithelium in human ADPKD and ARPKD
and in murine models of these diseases [33–35, 38]. The
abnormally expressed apical receptors are capable of
high-affinity EGF binding and autophosphorylation and
initiate a signaling cascade that results in cell prolifera-
tion [35]. To this end, our results demonstrate that EGFR
expression was increased, while c-myc and EGF expres-
sions were unchanged in the kidney of homozygous ProT
transgenic mice. This suggests that renal expression of
EGFR may be affected by ProT overexpression. Since
c-myc directly regulates the expression of ProT gene by
binding to the E box of its promoter [25, 26], whether
c-myc regulates EGFR expression through ProT in vivo
remains to be elucidated. Furthermore, the lack of sig-
nificant alteration in c-myc expression provides further
evidence that the PKD phenotype noted in ProT trans-
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Fig. 10. Effects of prothymosin a (ProT) overexpression on mRNA
expressions of c-myc, epithelial growth factor receptor (EGFR), and
epithelial growth factor (EGF) in the kidney. Total renal RNA was ex-
tracted from T9 homozygous (HZ), heterozygous (HET), and nontrans-
genic (NT) mice, as well as from wild-type (WT) mice. (A) Expressions
of c-myc, EGFR, and EGF mRNA, as well as ProT transgenic mRNA
were examined by reverse transcription-polymerase chain reaction (RT-
PCR). 18S rRNA served as an internal control. M is 100 bp DNA ladder
as molecular size standard. (B) Bar chart showing comparative densit-
ometric analysis of various RT-PCR products relative to 18S rRNA in
renal tissues of the mice. The expression analysis was repeated three
times. ∗∗P < 0.01; ∗P < 0.05.
genic mice did not result from c-myc activation, prob-
ably arising from an “integration position effect.” It is
well documented that ProT promotes cell proliferation
[17–20]. In ProT transgenic mice described here, renal
cyst development always occurred in newborn mice and
cyst number and size increased with age, suggesting that
overexpression of ProT may affect kidney development
through promoting tubular epithelium proliferation dur-
ing embryo development, resulting in the development
of PKD. However, the underlying molecular mechanism
still awaits further investigation. Recently, EKI-785, an
EGFR tyrosine kinase inhibitor, has been demonstrated
to attenuate PKD development in a mouse ARPKD
model [39] and a rat ADPKD model [40]. Since our
data indicate that ProT overexpression leads to EGFR
up-regulation in the kidneys of homozygous ProT trans-
genic mice and that renal ProT is overexpressed in
the clinical specimens of ARPKD and ADPKD cases,
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suppression of ProT overexpression might be a consider-
able approach for ameliorating the symptoms of PKD. So
far, there is no proper molecular maker available for the
diagnosis of PKD. We have demonstrated abundant dis-
tribution of ProT not only in cystic kidneys but also in the
urine of homozygous ProT transgenic mice that resemble
human ARPKD. In particular, the content of ProT pro-
tein in the urine of homozygous ProT transgenic mice was
ten times greater compared with heterozygous or non-
transgenic littermates. Therefore, ProT might represent
a candidate molecular marker for noninvasive diagnosis
of PKD if further studies using sufficient samples prove
its feasibility.
Taken together, ProT transgenic mice represent a novel
PKD animal model resembling human ARPKD. The rel-
evance of this model to the human disease is further
supported by ProT overexpression observed in both hu-
man ARPKD and ADPKD kidneys. However, the role
of ProT in the cystogenesis still remains to be clarified.
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